

Lamont, Jennifer

From: Sarah Buckley [REDACTED]
Sent: 05 March 2013 08:45
To: Lamont, Jennifer
Subject: Fw: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

"This email is covered by the disclaimer found at the end of the message."

Jennifer,
Please find confirmation below,
Sarah

From: Duly, Ellie [REDACTED]
Sent: Monday, March 04, 2013 06:31 PM GMT Standard Time
To: Sarah Buckley
Subject: Re: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

Yes. We should NOT change ref range

From: Sarah Buckley [REDACTED]
Sent: Monday, March 04, 2013 03:43 PM
To: Duly, Ellie
Subject: FW: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

"This email is covered by the disclaimer found at the end of the message."

Ellie
Please see below query from Jennifer, I take it the answer is yes?
Sarah

Sarah Buckley
Manager, Northern Ireland Pathology Network
First Floor, IT Department
Back Entrance - Knockbracken Clinic
Knockbracken Healthcare Park
Saintfield Road
Belfast
BT8 8BH

Telephone: [REDACTED]
Email: [REDACTED]

From: Lamont, Jennifer [REDACTED]
Sent: 04 March 2013 15:26
To: Sarah Buckley
Subject: RE: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

Sarah, apologies, but can you confirm that where the chart says the following against the fluid deficit criteria:

ESTIMATE DEFICIT

FLUID DEFICIT = (% dehydration x kg x 10) as mls of:

sodium chloride 0.9%

The volume of fluid to be prescribed is: fluid deficit MINUS volume of any fluid bolus received

Prescribe this residual volume of deficit separately from the maintenance prescription.

Give over 24 hours (but over 48 hours if Na+ < 135 or > 145 mmol/L)

ONGOING LOSSES: calculate at least 4 hourly. Replace with an equal volume of:

sodium chloride 0.9% (with or without pre-added potassium)

Be prepared to change fluid type and volume according to clinical reassessment, electrolyte losses and test results

We should NOT change the reference from Na+ <135 to reflect the change in the base limit to 133?

Jennifer

From: Sarah Buckley [REDACTED]
Sent: 04 March 2013 15:06
To: Lamont, Jennifer
Subject: RE: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

"This email is covered by the disclaimer found at the end of the message."

You're welcome Jennifer
Sarah

Sarah Buckley
Manager, Northern Ireland Pathology Network
First Floor, IT Department
Back Entrance - Knockbracken Clinic
Knockbracken Healthcare Park
Saintfield Road
Belfast
BT8 8BH

Telephone: [REDACTED]
Email: [REDACTED]

From: Lamont, Jennifer [REDACTED]
Sent: 04 March 2013 15:04
To: Sarah Buckley
Cc: Ellie Duly (niecr); Welsh, Jennifer
Subject: RE: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

Sarah, many thanks.

Jennifer

From: Sarah Buckley [REDACTED]
Sent: 04 March 2013 15:05
To: Lamont, Jennifer
Cc: Ellie Duly (niecr); Welsh, Jennifer

Subject: FW: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart
Importance: High

"This email is covered by the disclaimer found at the end of the message."

Jennifer,


In response to your recent query on the wall chart on paediatric parenteral fluid therapy, Ellie Duly, Chair of the Biochemistry Specialty Forum has consulted with Forum members and provided the response below.

Please do not hesitate to contact me if you have any further queries,

Yours sincerely,

Sarah

Sarah Buckley
Manager, Northern Ireland Pathology Network
First Floor, IT Department
Back Entrance - Knockbracken Clinic
Knockbracken Healthcare Park
Saintfield Road
Belfast
BT8 8BH



From: Duly, Ellie [REDACTED]
Sent: 04 March 2013 14:56
To: Sarah Buckley; [brian.cairns](#) [REDACTED]; [derek.mckillop](#) [REDACTED]; Hanna, Elinor; Kevan Duffin; Kevin Stoker; Margaret McDonnell; Mark Lynch; Maurice.o'kane [REDACTED]; McBride, David; McGowan, Noel; Mike Ryan; Peter Auld; Sarah BUCKLEY
Subject: RE: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart
Importance: High

Sarah

I have consulted with colleagues

1. Nothing should be done to Na <130 mmol/L
2. Glucose testing is acceptable

In other words the chart is fine as it stands

Best wishes

Ellie Duly

Chair of Regional Bio Forum

From: Sarah Buckley [REDACTED]
Sent: 01 March 2013 08:46
To: Duly, Ellie
Subject: Re: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

◆ This email is covered by the disclaimer found at the end of the message. ◆

Thanks!

From: Duly, Ellie [REDACTED]
Sent: Friday, March 01, 2013 08:44 AM GMT Standard Time
To: brian.cairns [REDACTED] <brian.cairns [REDACTED]>; derek.mckillop [REDACTED] <derek.mckillop [REDACTED]>; Hanna, Elinor [REDACTED]; Kevan Duffin <kevan.duffin [REDACTED]>; Kevin Stoker [REDACTED]; Margaret McDonnell <margaret.mcdonnell [REDACTED]>; Mark Lynch [REDACTED]; Maurice.o'kane [REDACTED]; McBride, David [REDACTED]; McGowan, Noel <Noel.McGowan [REDACTED]>; Mike Ryan [REDACTED]; Peter Auld <peter.auld [REDACTED]>; Sarah BUCKLEY [REDACTED]
Subject: FW: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

Hi all

Could you please have a look at the attached chart. 2 areas for consideration:

1. Should anything be done to Na < 130 mmol/L in view of the fact that Path Harmonisation resulted in a change in bottom of our Na reference range from 135-133 mmol/L

2. The reference to "plasma glucose testing" (we are amending this to say "glucose testing" in order to capture point of care tests)

This needs to be done ASAP- so I will take comments until Tues 5th- they can't wait for our next meeting. Can you discuss/ forward this with other Chem Path/ Clin Biochem in your trusts who are not sitting on the forum currently

The email trail below will give a fuller explanation

Thank you

Ellie

From: Lamont, Jennifer [REDACTED]
Sent: 28 February 2013 11:18
To: Sarah Buckley; Duly, Ellie
Cc: Welsh, Jennifer
Subject: RE: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

Attached above.

Jennifer

From: Sarah Buckley [REDACTED]
Sent: 28 February 2013 11:15
To: Lamont, Jennifer; Ellie Duly (niecr)
Cc: Campbell, Karen (DHSSPS); Welsh, Jennifer
Subject: RE: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

"This email is covered by the disclaimer found at the end of the message. ♦"

Thanks Jennifer,

If you could please send through the poster as is at the mo we could try to facilitate an e-discussion on this, will link with Ellie to see how quickly we can reasonably get this to you and will try to expedite,
Sarah

Sarah Buckley
Manager, Northern Ireland Pathology Network
First Floor, IT Department
Back Entrance - Knockbracken Clinic
Knockbracken Healthcare Park
Saintfield Road
Belfast
BT8 8BH

[REDACTED]

From: Lamont, Jennifer [REDACTED]
Sent: 28 February 2013 10:44
To: Sarah Buckley; Ellie Duly (niecr)
Cc: Welsh, Jennifer; Campbell, Karen (DHSSPS)
Subject: RE: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

Sarah, many thanks for getting in touch so quickly.

Given the nature of this work, we are keen to issue the revised wallchart as soon as possible and I'd be grateful if it were possible to consider and advise on the amendment before 20th March – as soon as at all possible in fact.

I appreciate this may not be easily achieved, but would be very grateful if you could find a way to bring this forward.

Jennifer

[REDACTED]

From: Sarah Buckley [REDACTED]
Sent: 28 February 2013 09:13
To: Lamont, Jennifer; Ellie Duly (niecr)
Cc: Welsh, Jennifer
Subject: RE: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

"This email is covered by the disclaimer found at the end of the message. ♦"

Jennifer,

It would be helpful to know the date by which you require confirmation from the Biochemistry Specialty Forum on this. The Forum is next due to meet on 20th March. Can you hold off until then or is there more urgency?

Thank you

Sarah

Sarah Buckley

Manager, Northern Ireland Pathology Network

First Floor, IT Department

Back Entrance - Knockbracken Clinic

Knockbracken Healthcare Park

Saintfield Road

Belfast

BT8 8BH

From: Welsh, Jennifer [REDACTED]

Sent: 27 February 2013 23:30

To: 'Lamont, Jennifer'; Ellie Duly (niecr)

From: Sarah Buckley

Subject: RE: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart

Jennifer

This matter is being taken forward by the Biochemistry Specialty Forum – which is a sub-group of the Pathology Network Board – and is chaired by Ellie Duly.

Ellie, I would be grateful if you would liaise with Jennifer on this.

Many thanks

Jennifer

From: Lamont, Jennifer [REDACTED]

Sent: 26 February 2013 10:00

To: Welsh, Jennifer

Subject: Potential Change to Paediatric Parenteral Fluid Therapy Wallchart


Jennifer, by way of introduction, I work in Standards & Guidelines Quality Unit in the Department and am currently liaising with colleagues to re-print an amended version of the wallchart on paediatric parenteral fluid therapy.

The change we have requested is a minor one to the reference to “plasma glucose testing” (we are amending this to say “glucose testing” in order to capture point of care tests) and I include the draft amended chart for reference. However, I have been made aware of another potential change as a result of a recent decision by the NI Pathology Network in regards to sodium levels.

I would be very grateful if you could advise if the Network has recommended such a change so that I can consult with the group that produced the guidance and ensure any necessary changes are made to the wallchart at this stage rather than arrange another re-print in the near future.

Many thanks,

Jennifer Lamont
Standards & Guidelines Quality Unit



"The information contained in this email and any attachments is confidential and intended solely for the attention and use of the named addressee(s). No confidentiality or privilege is waived or lost by any mistransmission. If you are not the intended recipient of this email, please inform the sender by return email and destroy all copies. Any views or opinions presented are solely those of the author and do not necessarily represent the views of HSCNI. The content of emails sent and received via the HSC network may be monitored for the purposes of ensuring compliance with HSC policies and procedures. While HSCNI takes precautions in scanning outgoing emails for computer viruses, no responsibility will be accepted by HSCNI in the event that the email is infected by a computer virus. Recipients are therefore encouraged to take their own precautions in relation to virus scanning. All emails held by HSCNI may be subject to public disclosure under the Freedom of Information Act 2000. ♦

"The information contained in this email and any attachments is confidential and intended solely for the attention and use of the named addressee(s). No confidentiality or privilege is waived or lost by any mistransmission. If you are not the intended recipient of this email, please inform the sender by return email and destroy all copies. Any views or opinions presented are solely those of the author and do not necessarily represent the views of HSCNI. The content of emails sent and received via the HSC network may be monitored for the purposes of ensuring compliance with HSC policies and procedures. While HSCNI takes precautions in scanning outgoing emails for computer viruses, no responsibility will be accepted by HSCNI in the event that the email is infected by a computer virus. Recipients are therefore encouraged to take their own precautions in relation to virus scanning. All emails held by HSCNI may be subject to public disclosure under the Freedom of Information Act 2000. ♦

♦The information contained in this email and any attachments is confidential and intended solely for the attention and use of the named addressee(s). No confidentiality or privilege is waived or lost by any mistransmission. If you are not the intended recipient of this email, please inform the sender by return email and destroy all copies. Any views or opinions presented are solely those of the author and do not necessarily represent the views of HSCNI. The content of emails sent and received via the HSC network may be monitored for the purposes of ensuring compliance with HSC policies and procedures. While HSCNI takes precautions in scanning outgoing emails for computer viruses, no responsibility will be accepted by HSCNI in the event that the email is infected by a computer virus. Recipients are therefore encouraged to take their own precautions in relation to virus scanning. All emails held by HSCNI may be subject to public disclosure under the Freedom of Information Act 2000. ♦

"The information contained in this email and any attachments is confidential and intended solely for the attention and use of the named addressee(s). No confidentiality or privilege is waived or lost by any mistransmission. If you are not the intended recipient of this email, please inform the sender by return email and destroy all copies. Any views or opinions presented are solely those of the author and do not necessarily represent the views of HSCNI. The content of emails sent and received via the HSC network may be monitored for the purposes of ensuring compliance with HSC policies and procedures. While HSCNI takes precautions in scanning outgoing emails for computer viruses, no responsibility will be accepted by HSCNI in the event that the email is infected by a computer virus. Recipients are therefore encouraged to take their own precautions in relation to virus scanning. All emails held by HSCNI may be subject to public disclosure under the Freedom of Information Act 2000."

"The information contained in this email and any attachments is confidential and intended solely for the attention and use of the named addressee(s). No confidentiality or privilege is waived or lost by any mistransmission. If you are not the intended recipient of this email, please inform the sender by return email and destroy all copies. Any views or opinions presented are solely those of the author and do not necessarily represent the views of HSCNI. The content of emails sent and received via the HSC network may be monitored for the purposes of ensuring compliance with HSC policies and procedures. While HSCNI takes precautions in scanning outgoing emails for computer viruses, no responsibility will be accepted by HSCNI in the event that the email is infected by a computer virus. Recipients are therefore encouraged to take their own precautions in relation to virus scanning. All emails held by HSCNI may be subject to public disclosure under the Freedom of Information Act 2000."

"The information contained in this email and any attachments is confidential and intended solely for the attention and use of the named addressee(s). No confidentiality or privilege is waived or lost by any mistransmission. If you are not the intended recipient of this email, please inform the sender by return email and destroy all copies. Any views or opinions presented are solely those of the author and do not necessarily represent the views of HSCNI. The content of emails sent and received via the HSC network may be monitored for the purposes of ensuring compliance with HSC policies and procedures. While HSCNI takes precautions in scanning outgoing emails for computer viruses, no responsibility will be accepted by HSCNI in the event that the email is infected by a computer virus. Recipients are therefore encouraged to take their own precautions in relation to virus scanning. All emails held by HSCNI may be subject to public disclosure under the Freedom of Information Act 2000."

"The information contained in this email and any attachments is confidential and intended solely for the attention and use of the named addressee(s). No confidentiality or privilege is waived or lost by any mistransmission. If you are not the intended recipient of this email, please inform the sender by return email and destroy all copies. Any views or opinions presented are solely those of the author and do not necessarily represent the views of HSCNI. The content of emails sent and received via the HSC network may be monitored for the purposes of ensuring compliance with HSC policies and procedures. While HSCNI takes precautions in scanning outgoing emails for computer viruses, no responsibility will be accepted by HSCNI in the event that the email is infected by a computer virus. Recipients are therefore encouraged to take their own precautions in relation to virus scanning. All emails held by HSCNI may be subject to public disclosure under the Freedom of Information Act 2000."